Get started
Author

Sarah Leeth Hansen Farmer

Observed names: Farmer, Sarah, Farmer, Sarah Leeth Hansen, S. Farmer, S. Leeth Farmer, Sarah Farmer, Sarah Leeth Farmer
ORCID: 0000-0001-7525-7765
Observed ORCID: 0000-0001-7525-7765
OpenAlex ID: A5031270025
Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population‐based cohort study
2013 · Sarah Farmer, Erzsébet Horváth‐Puhó, et al. · British Journal of Haematology · 50
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
2026 · Cyrille Touzeau, Roberto Mina, et al. · New England Journal of Medicine · 33
Bone morbidity in chronic myeloproliferative neoplasms
2015 · Sarah Farmer, Lukas Frans Ocias, et al. · Expert Review of Hematology · 15
Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers
2015 · Sarah Farmer, Hanne Vestergaard, et al. · International Journal of Hematology · 15
Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera
2016 · S. Farmer, V. V. Shanbhogue, et al. · Osteoporosis International · 9
Real-world use, safety, and efficacy of teclistamab with or without prophylactic tocilizumab in relapsed/refractory multiple myeloma; Results from the danish ABCD study.
2025 · Astrid Hundeboell Torpe, Jonathan Thorsen, et al. · Blood · 6
PDF
[Severe osteoporosis in a patient with polycythaemia vera].
2014 · Sarah Farmer, Anne Pernille Hermann, et al. · PubMed · 4
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
2026 · Katarina Uttervall, Martin K. Kortum, et al. · Haematologica · 3
PDF
Mitigating Teclistamab Toxicity: Prophylactic Tocilizumab and Timing of Immunoglobulin Replacement Therapy in a Nationwide Cohort
2026 · Astrid Hundebøll Torpe, Jonathan Thorsen, et al. · American Journal of Hematology · 1
PDF
A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group
2024 · Diana Loigom, Tobias S. S. Slørdahl, et al. · Blood · 1
[Status and perspectives on chronic myeloproliferative neoplasm treatment].
2015 · Lukas Frans Ocias, Morten Orebo Holmström, et al. · PubMed · 1
Frailty and quality of life in a real‐world multiple myeloma population
2026 · Klara F. K. Rydahl, Sören Möller, et al. · British Journal of Haematology
PDF
Frailty and Quality of Life in Newly Diagnosed Multiple Myeloma Patients
2026 · Rydahl, Klara Frederikke Koue; id_orcid 0000-0002-4705-2866, Horsbøl, Trine Allerslev; id_orcid 0000-0002-1278-9198, et al. · University of Southern Denmark Research Portal (University of Southern Denmark)
Real-World Outcomes of Teclistamab in Heavily Pretreated Relapsed/Refractory Multiple Myeloma With True Extramedullary Disease: Results From the Danish ABCD Study
2026 · Torpe, Astrid Hundebøll, Thorsen, Jonathan, et al. · University of Southern Denmark Research Portal (University of Southern Denmark)
Effectiveness, Safety and Clinical use of Teclistamab in Patients with Triple-Class-Exposed Multiple Myeloma. Data from the Danish ABC-Study
2025 · Astrid Hundebøll Torpe, Jonathan Thorsen, et al. · Clinical Lymphoma Myeloma & Leukemia
A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
2025 · Diana Loigom, Tobias Schmid Slørdahl, et al. · Clinical Lymphoma Myeloma & Leukemia
Real-world effectiveness of belantamab mafodotin, BCMA-CD3 bispecific antibodies and talquetamab in patients with triple-class-exposed multiple myeloma. First results from the Danish ABCD-study
2025 · Torpe, Astrid Hundebøll, Thorsen, Jonathan, et al.
Anæmi i almen praksis
2017 · Louise Hur Hannig, Sarah Leeth Hansen Farmer · University of Southern Denmark Research Portal (University of Southern Denmark)
Myeloproliferative neoplasms and bone morbidity
2015 · Sarah Leeth Hansen Farmer
Erratum to: Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers
2015 · Sarah Farmer, Hanne Vestergaard, et al. · International Journal of Hematology
PDF
Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier
2015 · Lukas Frans Ocias, Morten Orebo Holmström, et al. · VBN Forskningsportal (Aalborg Universitet)
Knoglemineralindhold hos patienter med ET og PV
2015 · Sarah Leeth Hansen Farmer
Bone Manifestations in Patients with Myelofibrosis - A Cross-Sectional Study Using DXA and HR-PQCT
2014 · Sarah Leeth Hansen Farmer, Henrik Frederiksen, et al.
Bone structure in patients with myelofibrosis - A cross-sectional study using DXA and HR-pQCT
2014 · Hanne Vestergaard, Sarah Leeth Hansen Farmer, et al. · University of Southern Denmark Research Portal (University of Southern Denmark)
Patienter med kronisk myeloproliferative neoplasier har øget risiko for frakturer viser et landsdækkende populationsbaseret kohortestudie
2014 · Sarah Leeth Hansen Farmer · University of Southern Denmark Research Portal (University of Southern Denmark)
Works count: 30
Citation count: 138
H-index: 6
I10-index: 4
Year
Topic
Type